Relay Therapeutics, Inc. - Common Stock (NQ:RLAY)

8.840 +0.140 (+1.61%)

Streaming Delayed Price Updated: 2:03 PM EST, Feb 23, 2026 Add to My Watchlist

Price and Volume

Volume	420,414
Open	8.660
Bid (Size)	8.830 (100)
Ask (Size)	8.850 (300)
Prev. Close	8.700
Today's Range	8.645 - 9.005
52wk Range	1.775 - 9.540
Shares Outstanding	121,613,181
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer ↗

Today 10:57 EST

Agios Pharmaceuticals develops therapies for rare blood disorders, anchored by its PYRUKYND franchise and early-stage clinical programs.

Via The Motley Fool

Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake ↗

Today 10:46 EST

Viridian Therapeutics develops monoclonal antibody therapies targeting rare diseases, with a focus on thyroid eye disease treatments.

Via The Motley Fool

Performance

YTD	+8.1%	+8.1%
1 Month	+19.0%	+19.0%
3 Month	+8.2%	+8.2%
6 Month	+151.9%	+151.9%
1 Year	+127.8%	+127.8%

More News

Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million ↗

Today 10:38 EST

Via The Motley Fool

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

Biotech Fund Dumps 1.85 Million Centessa Shares as Stock Jumps Over 50% ↗

Today 10:29 EST

Via The Motley Fool

Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29% ↗

Today 10:21 EST

Via The Motley Fool

Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights on February 26, 2026

February 19, 2026

From Relay Therapeutics, Inc.

Via GlobeNewswire

Relay Therapeutics Insider Sells 21,000 Shares for $166,700 After 65% Run ↗

February 06, 2026

Via The Motley Fool

Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026

February 04, 2026

From Relay Therapeutics, Inc.

Via GlobeNewswire

Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer

February 03, 2026

From Relay Therapeutics, Inc.

Via GlobeNewswire

The Sound of Silence: Revolution Medicines Plummets 17% as M&A Hopes Evaporate

February 02, 2026

Via MarketMinute

Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards

December 16, 2025

From Equity Insider

Via GlobeNewswire

Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025

December 12, 2025

From Relay Therapeutics, Inc.

Via GlobeNewswire

Relay Therapeutics Director Sells $300,000 Worth of Shares. Here's Why Investors Shouldn't Panic. ↗

December 03, 2025

Via The Motley Fool

Relay Therapeutics Stock Has Jumped 60% in a Year — And One Investor Just Bought Nearly 4 Million More Shares ↗

December 03, 2025

Via The Motley Fool

Beyond the Hype: AI’s Quiet Revolution in Niche Sectors Reshapes Industries from Medicine to Agriculture

December 01, 2025

Via TokenRing AI

Relay Therapeutics Inc (NASDAQ:RLAY) Reports Q3 2025 Earnings Miss and Clinical Progress ↗

November 06, 2025

Via Chartmill

Relay Therapeutics Reports Third Quarter 2025 Financial Results and Corporate Updates

November 06, 2025

From Relay Therapeutics, Inc.

Via GlobeNewswire

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in November

November 03, 2025

From Relay Therapeutics, Inc.

Via GlobeNewswire

Relay Therapeutics to Announce Third Quarter 2025 Financial Results and Corporate Highlights on November 6, 2025

October 30, 2025

From Relay Therapeutics, Inc.

Via GlobeNewswire

Why Relay Therapeutics Stock Rocketed Nearly 15% Higher This Week ↗

September 05, 2025

Via The Motley Fool

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September

August 28, 2025

From Relay Therapeutics, Inc.

Via GlobeNewswire

Medtronic To Rally Around 25%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

August 26, 2025

Via Benzinga

Relay (RLAY) Q2 Loss Narrows 41% ↗

August 07, 2025

Via The Motley Fool

Relay Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates

August 07, 2025

From Relay Therapeutics, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Relay Therapeutics, Inc. - Common Stock publicly traded?

Yes, Relay Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Relay Therapeutics, Inc. - Common Stock trade on?

Relay Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Relay Therapeutics, Inc. - Common Stock?

The ticker symbol for Relay Therapeutics, Inc. - Common Stock is RLAY on the Nasdaq Stock Market

What is the current price of Relay Therapeutics, Inc. - Common Stock?

The current price of Relay Therapeutics, Inc. - Common Stock is 8.840

When was Relay Therapeutics, Inc. - Common Stock last traded?

The last trade of Relay Therapeutics, Inc. - Common Stock was at 02/23/26 02:03 PM ET

What is the market capitalization of Relay Therapeutics, Inc. - Common Stock?

The market capitalization of Relay Therapeutics, Inc. - Common Stock is 1.08B

How many shares of Relay Therapeutics, Inc. - Common Stock are outstanding?

Relay Therapeutics, Inc. - Common Stock has 1B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.